Key facts
- ProVerum’s last known valuation is $147.3M (Aug 2025).
- It has raised $123.8M; the latest was Later Stage VC ($80.0M) in Aug 2025.
- Notable investors include Enterprise Ireland, OrbiMed, Atlantic Bridge Capital, Gilde Healthcare, Lightstone Ventures — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for ProVerum
- ·The full record, as it builds
Funding rounds
No funding rounds for ProVerum are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ProVerum
Manufacturer of a medical device intended to alleviate symptoms caused by an enlarged prostate. The company's flexible delivery system that uses 3-D geometry to engage prostate anatomy, providing radial force to the prostatic lobes without cutting, piercing, or heating tissue, with features including precise deployment under direct visualization, reversibility for removal at any time, an atraumatic design that reduces bleeding and the need for catheterization, and a universal fit to accommodate all indicated anatomies, enabling healthcare providers to treat patients experiencing urinary obstruction caused by prostate enlargement effectively.
- Sector
- Healthcare
- HQ
- Dublin, Ireland
- Founded
- 2016
- Employees
- 33
- Website
- proverummedical.com/
- Ownership
- Privately Held (backing)
ProVerum doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ProVerum shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ProVerum in its N-PORT filings yet. We sweep new filings monthly.